<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216967</url>
  </required_header>
  <id_info>
    <org_study_id>6646</org_study_id>
    <nct_id>NCT03216967</nct_id>
  </id_info>
  <brief_title>Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.</brief_title>
  <acronym>BK EVER</acronym>
  <official_title>Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia After Reduction of Immunosuppression Alone vs. Reduction of Immunosuppression and Replacement of Mycophenolate Mofetil by Everolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BK virus nephropathy (BKVN), a consequence of the strong immunosuppressive therapy given
      after kidney transplantation, represents a growing problem in the kidney transplant (KT)
      setting. In recent cohorts, BKVN concerns up to 10% of kidney transplant recipients and early
      signs of BK virus (BKV) infection as development of asymptomatic viruria and viremia are even
      much more frequent (40% and 20% of patients, respectively). In this context, finding
      strategies to prevent BKV infection or treat patients before the occurrence of BKV
      nephropathy is challenging. For several years, detection of BKV replication by real-time PCR
      in urine and/or blood of kidney transplant recipients at early stages of infection allowed
      adaptation of their therapy. As BKV reactivates essentially in patients with
      over-immunosuppression, the first step of the treatment is the reduction of
      immunosuppression. However, reducing immunosuppression (IS) can lead to acute rejection and
      allograft loss. Other treatments have been proposed (cidofovir, quinolones) but their
      toxicity profile or their lack of clinical efficacy are now demonstrated. Hence, an efficient
      and safe strategy against uncontrolled BKV replication is urgently needed. MTor-inhibitors
      are well known immunosuppressive drugs used in organ transplantation to prevent
      graft-rejection. They have furthermore anti-viral effects that can be beneficial for
      prevention of viral infections after transplantation. Recent evidence that inhibition of mTor
      pathway had an impact on BK infected cells provides additional insight into the observed
      benefits associated with these drugs. The aim of our study is to evaluate the effect of the
      mTor inhibitor everolimus on the prevention of severe BKV infection (BKV nephropathy or loss
      of the allograft) after kidney transplantation compared to the reduction of immunosuppression
      alone in kidney recipients with BK viremia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main objective of our study is to evaluate the proportion of patients with BKV clearance 6 months after introduction of everolimus in kidney recipients who develop BKV viremia compared to patients managed with IS reduction alone</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>The primary end point is the proportion of patients with clearance of BK viremia assessed by blood PCR and functional graft 6 months after modification of immunosuppressive therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>BK Virus Nephropathy After Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>IS lowering alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50% decrease of the dose of mycophenolic acid at M1 (target AUC 20 mg.h/L)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus + IS lowering</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stop mycophenolate acid (Cellcept or myfortic) Introduction of everolimus : 2 x 0.75 mg/d per os in patiens treated by ciclosporine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>Patients with viremia above 3 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization</description>
    <arm_group_label>IS lowering alone</arm_group_label>
    <arm_group_label>Everolimus + IS lowering</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients

          -  Kidney transplant recipients

          -  Patients treated by a calcineurin inhibitor and mycophenolic acid

          -  Viremia &gt;= 3 log UI/ml

          -  Patients who have given written informed consent

          -  Negative pregnancy test (blood β-HCG dosage)

        Exclusion Criteria:

          -  Known proved BKV nephropathy

          -  Hypersensitivity to everolimus, sirolimus or excipient

          -  Concomitant treatment by leflunomide, cidofovir, sirolimus, Millepertuis (Hypericum
             Perforatum)

          -  Pregnant or lactating women

          -  Women of child bearing potential unless they are using a birth control method
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie Caillard</last_name>
    <phone>0369550511</phone>
    <email>sophie.caillard@chru-strasboourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU - Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maité JAUREGUY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johnny SAYEGH, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital de la Cavale Blanche</name>
      <address>
        <city>Bois-guillaume</city>
        <zip>76230</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique BERTRAND, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yannick LE MEUR, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas BOUVIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Elisabeth HENG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Philippe REROLLE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dany ANGLICHEAU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric THERVET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers - Hôpital Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure ECOTIERE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Betoul SCHVARTZ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Léonard GOLBIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie CAILLARD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias BUCHLER, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

